Remove Cardiovascular Disease Remove Myocardial Infarction Remove Risk Factors
article thumbnail

Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease

DAIC

mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J.

article thumbnail

No Plaque, No Problem: Tackling Atherosclerosis Prevention

Cardiometabolic Health Congress

Atherosclerosisa key driver of cardiovascular disease (CVD)continues to be a significant global health issue. This imbalance is partly due to limited healthcare access, fewer preventive resources, and challenges in addressing risk factors such as obesity and diabetes.

article thumbnail

Unraveling the Link Between Mental Health and Cardiovascular Disease 

Cardiometabolic Health Congress

Other studies have also unearthed more intricate connections which suggests that physiological conditions, underpinned by biological and chemical factors, may also play a pivotal role in influencing cardiovascular disease (CVD). In 2021 alone, CVD accounted for over 900,000 deaths in the U.S. and approximately 19.91

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

article thumbnail

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan area of Brandenburg, Germany

Frontiers in Cardiovascular Medicine

Background and aims In the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. vs. 53.2%, p  = 0.014) and myocardial infarction (24.7%

article thumbnail

In‐Hospital Outcomes in Patients With Acute Myocardial Infarction and No Standard Modifiable Cardiovascular Risk Factors Across Varying Body Mass Index: Findings From the CCC‐ACS Project

Journal of the American Heart Association

Multivariable logistic regression models were used to estimate BMIstratified associations between SMuRFless status and outcomes.ResultsThe study included 44 538 patients with firstpresentation acute myocardial infarction, of whom 4454 were SMuRFless. Journal of the American Heart Association, Ahead of Print.

article thumbnail

Abstract 4148106: Hemophilia and Cardiovascular disease in the United States: Prevalence, Risk factors, and outcomes.

Circulation

Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population.